The therapeutic age of the neonatal Fc receptor
IgGs are essential soluble components of the adaptive immune response that evolved to
protect the body from infection. Compared with other immunoglobulins, the role of IgGs is …
protect the body from infection. Compared with other immunoglobulins, the role of IgGs is …
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is the
most recently defined inflammatory demyelinating disease of the central nervous system …
most recently defined inflammatory demyelinating disease of the central nervous system …
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 …
Background Generalised myasthenia gravis is a chronic, unpredictable, and debilitating
autoimmune disease. New treatments for this disease are needed because conventional …
autoimmune disease. New treatments for this disease are needed because conventional …
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non …
Background Chimeric antigen receptor (CAR) T cells are highly effective in treating
haematological malignancies, but associated toxicities and the need for lymphodepletion …
haematological malignancies, but associated toxicities and the need for lymphodepletion …
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study
JF Howard, S Bresch, A Genge… - The Lancet …, 2023 - thelancet.com
Background Generalised myasthenia gravis is a chronic, unpredictable, and debilitating rare
disease, often accompanied by high treatment burden and with an unmet need for more …
disease, often accompanied by high treatment burden and with an unmet need for more …
International consensus guidance for management of myasthenia gravis: 2020 update
Objective To update the 2016 formal consensus-based guidance for the management of
myasthenia gravis (MG) based on the latest evidence in the literature. Methods In October …
myasthenia gravis (MG) based on the latest evidence in the literature. Methods In October …
Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD)–revised recommendations of the Neuromyelitis Optica Study Group …
T Kümpfel, K Giglhuber, O Aktas, I Ayzenberg… - Journal of …, 2024 - Springer
This manuscript presents practical recommendations for managing acute attacks and
implementing preventive immunotherapies for neuromyelitis optica spectrum disorders …
implementing preventive immunotherapies for neuromyelitis optica spectrum disorders …
Terminal complement inhibitor ravulizumab in generalized myasthenia gravis
Background Generalized myasthenia gravis (gMG) is a rare, chronic, and debilitating
autoimmune disease. Activation of the complement system by autoantibodies against the …
autoimmune disease. Activation of the complement system by autoantibodies against the …
[PDF][PDF] Myasthenia gravis: the future is here
HJ Kaminski, P Sikorski, SI Coronel, LL Kusner - Journal of Clinical …, 2024 - jci.org
Myasthenia gravis (MG) stands as a prototypical antibody-mediated autoimmune disease: it
is dependent on T cells and characterized by the presence of autoantibodies targeting …
is dependent on T cells and characterized by the presence of autoantibodies targeting …
Impact of structural modifications of IgG antibodies on effector functions
T Damelang, M Brinkhaus, TLJ van Osch… - Frontiers in …, 2024 - frontiersin.org
Immunoglobulin G (IgG) antibodies are a critical component of the adaptive immune system,
binding to and neutralizing pathogens and other foreign substances. Recent advances in …
binding to and neutralizing pathogens and other foreign substances. Recent advances in …